| Bile acid sequestrants and diabetes: introduction and overview to the supplement. | |
| | |
MedLine Citation:
|
PMID: 20973745 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Diabetes is a global epidemic. The recommended goals for glycated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-C), and blood pressure are achieved only in a very small minority of patients. In this supplement to Metabolic Syndrome and Related Disorders, we review the data showing that the bile acid sequestrant colesevelam lowers both HbA1c and LDL-C in patients with diabetes. These data make colesevelam an attractive therapy to get more patients to achieve their LDL-C and HbA1c goals. |
| | |
Authors:
|
I Jialal |
Related Documents
:
|
8896905 - Impact of concentrations of glycated hemoglobin, alpha-tocopherol, copper, and manganes... 3529955 - High-density lipoprotein subclasses in diabetes. 16006255 - Circulating levels of nitrated apolipoprotein a-i are increased in type 2 diabetic pati... 9920155 - Association between low-density lipoprotein composition and its metabolism in non-insul... 14988235 - Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activa... 3522075 - Home monitoring of diabetes mellitus--a quiet revolution. |
Publication Detail:
|
Type: Introductory Journal Article; Research Support, N.I.H., Extramural Date: 2010-10-25 |
Journal Detail:
|
Title: Metabolic syndrome and related disorders Volume: 8 Suppl 1 ISSN: 1557-8518 ISO Abbreviation: Metab Syndr Relat Disord Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-12-14 Completed Date: 2011-03-31 Revised Date: 2011-12-21 |
Medline Journal Info:
|
Nlm Unique ID: 101150318 Medline TA: Metab Syndr Relat Disord Country: United States |
Other Details:
|
Languages: eng Pagination: S1-2 Citation Subset: IM |
Affiliation:
|
Laboratory for Atherosclerosis and Metabolic Research, University of California Davis Medical Center, Sacramento, California, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Allylamine
/
analogs & derivatives,
metabolism,
therapeutic use Animals Anticholesteremic Agents / metabolism*, therapeutic use* Bile Acids and Salts / antagonists & inhibitors, metabolism* Cholesterol, LDL / blood, drug effects Diabetes Mellitus / drug therapy* Hemoglobin A, Glycosylated / analysis, drug effects Humans |
| Grant Support | |
ID/Acronym/Agency:
|
K-24-AT00596/AT/NCCAM NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Bile Acids and Salts; 0/Cholesterol, LDL; 0/Hemoglobin A, Glycosylated; 0/hemoglobin A1c protein, human; 107-11-9/Allylamine; 182815-44-7/colesevelam |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Antioxidant supplementation improves platelet membrane fluidity in idiopathic retinal periphlebitis ...
Next Document: Enhanced endothelialization on surface modified poly(L-lactic acid) substrates.